<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945087</url>
  </required_header>
  <id_info>
    <org_study_id>OTF-1</org_study_id>
    <nct_id>NCT00945087</nct_id>
  </id_info>
  <brief_title>Experimental Phage Therapy of Bacterial Infections</brief_title>
  <official_title>Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences</source>
  <brief_summary>
    <textblock>
      The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages,&#xD;
      patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or&#xD;
      urinary tract infections in whom extensive antibiotic therapy failed or the use of the&#xD;
      targeted drug is contraindicated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial infections of different tissues and organs that prove incurable by antibiotics are&#xD;
      a serious clinical problem. Bacteriophages (phages) are bacterial viruses which attack,&#xD;
      multiply within, and then destroy bacteria. They can efficiently destroy bacteria which have&#xD;
      acquired resistance to antibiotics and which cause life-threatening infections. The method of&#xD;
      treating bacterial infections using phages has been known since the beginning of the 20th&#xD;
      century. This experimental treatment enables the use of phage preparations under the rules of&#xD;
      a therapeutic experiment (on the basis of the respective Polish regulations) in cases where&#xD;
      no effective available therapy exists or the use of the targeted drug is contraindicated. It&#xD;
      is not a research study.&#xD;
&#xD;
      The bacteriophage preparations which are used in the treatment procedures contain phages from&#xD;
      the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the&#xD;
      Polish Academy of Sciences in Wrocław. For each patient only specific formulations of single&#xD;
      phage or a phage mixture that are active against the pathogenic bacterial strain or strains&#xD;
      isolated from the patient are used for the treatment.The isolation of live bacterial pathogen&#xD;
      from the patient is necessary to carry out a phage-typing procedure to determine if the&#xD;
      preparation of an active formulation is possible which is a prerequisite for receiving the&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2005</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Bacterial Infections</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bacteriophage preparation</intervention_name>
    <description>Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.</description>
    <other_name>Phage preparation, bacteriophage formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or over.&#xD;
&#xD;
          -  Men and women of reproductive age must use contraception during and one month after&#xD;
             the therapy. Women of reproductive age must have negative result of a pregnancy test&#xD;
             before beginning of the treatment.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Antibiotic therapy-resistant, chronic, symptomatic bacterial infection of the skin,&#xD;
             subcutaneous tissue, bone, bone marrow, joints, fistulas, wounds, bedsores, genital&#xD;
             and/or urinary tract, digestive tract, middle ear, sinuses, tonsils, upper and lower&#xD;
             respiratory tract, or a state in which a targeted antibiotic therapy is impossible to&#xD;
             carry out due to other medical reasons.&#xD;
&#xD;
          -  A putative pathogenic bacteria such as Staphylococcus, Enterococcus, Escherichia,&#xD;
             Citrobacter, Enterobacter, Klebsiella, Shigella, Salmonella, Serratia, Proteus,&#xD;
             Pseudomonas, Stenotrophomonas, Acinetobacter, Burkholderia, or Morganella present in&#xD;
             the site of the said infection as confirmed by the result of microbiological culture.&#xD;
&#xD;
          -  Ineffective antibiotic therapy of said infection and/or antibiogram-confirmed&#xD;
             multidrug resistance of a putative pathogenic bacteria such as Staphylococcus,&#xD;
             Enterococcus, Escherichia, Citrobacter, Enterobacter, Klebsiella, Shigella,&#xD;
             Salmonella, Serratia, Proteus, Pseudomonas, Stenotrophomonas, Acinetobacter,&#xD;
             Burkholderia, or Morganella.&#xD;
&#xD;
          -  The presence in the Bacteriophage Collection of the Institute of Immunology and&#xD;
             Experimental Therapy of the Polish Academy of Sciences of a phage able to lyse a&#xD;
             bacterial strain cultured from a patient in the Bacteriophage Collection of the&#xD;
             Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences&#xD;
             (positive result of a phage-typing procedure).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Malabsorption syndrome, allergy to food or animal protein, or advanced hepatic&#xD;
             insufficiency when it is impossible to apply the phage preparation using other route&#xD;
             than oral.&#xD;
&#xD;
          -  Allergy to components of phage preparations.&#xD;
&#xD;
          -  A health condition which does not allow conducting the experimental therapy in the&#xD;
             opinion of the qualifying physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrzej Górski, M.D. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrzej Górski, M.D. Ph.D.</last_name>
    <phone>+48 71-3709905</phone>
    <email>agorski@ikp.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryszard Międzybrodzki, M.D. Ph.D.</last_name>
    <phone>+48 71-3709901</phone>
    <email>cm@iitd.pan.wroc.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phage Therapy Unit at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences</name>
      <address>
        <city>Wrocław</city>
        <zip>53-114</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrzej Górski, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryszard Międzybrodzki, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wojciech Fortuna, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krzysztof Szufnarowski, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sławomir Letkiewicz, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beata Weber-Dąbrowska, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paweł Rogóż, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://surfer.iitd.pan.wroc.pl/pl/OTF/</url>
    <description>Click here for more information about this study: Experimental phage therapy of drug-resistant bacterial infections, including MRSA infections (in Polish)</description>
  </link>
  <link>
    <url>http://surfer.iitd.pan.wroc.pl/en/Phages/</url>
    <description>Bacteriophage research and therapy</description>
  </link>
  <results_reference>
    <citation>Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawełczyk Z, Rogóż P, Kłak M, Wojtasik E, Górski A. Clinical aspects of phage therapy. Adv Virus Res. 2012;83:73-121. doi: 10.1016/B978-0-12-394438-2.00003-7. Review.</citation>
    <PMID>22748809</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <keyword>bacteriophage</keyword>
  <keyword>bacteriophage preparation</keyword>
  <keyword>bacterial infection</keyword>
  <keyword>antibiotic-resistant infection</keyword>
  <keyword>multidrug-resistant bacteria</keyword>
  <keyword>MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

